The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aadi Bioscience Inc | COM | 00032Q104 | 14,458,000 | 1,173,518 | SH | SOLE | 1,173,518 | 0 | 0 | |||
| Aclaris Therapeutics Inc | COM | 00461U105 | 63,713,000 | 4,563,962 | SH | SOLE | 4,563,962 | 0 | 0 | |||
| Aerovate Therapeutics Inc | COM | 008064107 | 9,228,000 | 590,408 | SH | SOLE | 590,408 | 0 | 0 | |||
| Affimed NV | COM | N01045108 | 3,957,000 | 1,428,571 | SH | SOLE | 1,428,571 | 0 | 0 | |||
| Akouos Inc | COM | 00973J101 | 12,509,000 | 2,667,119 | SH | SOLE | 2,667,119 | 0 | 0 | |||
| Altimmune Inc | COM | 02155H200 | 4,321,000 | 369,306 | SH | SOLE | 369,306 | 0 | 0 | |||
| Annexon Inc | COM | 03589W102 | 7,270,000 | 1,928,477 | SH | SOLE | 1,928,477 | 0 | 0 | |||
| aTyr Pharma Inc | COM | 002120202 | 3,959,000 | 1,398,889 | SH | SOLE | 1,398,889 | 0 | 0 | |||
| Celldex Therapeutics Inc | COM | 15117B202 | 23,324,000 | 865,116 | SH | SOLE | 865,116 | 0 | 0 | |||
| Chinook Therapeutics Inc | COM | 16961L106 | 8,563,000 | 489,618 | SH | SOLE | 489,618 | 0 | 0 | |||
| Cogent Biosciences Inc | COM | 19240Q201 | 36,424,000 | 4,038,117 | SH | SOLE | 4,038,117 | 0 | 0 | |||
| GH Research PLC | ORD SH | G3855L106 | 31,792,000 | 3,185,573 | SH | SOLE | 3,185,573 | 0 | 0 | |||
| Inozyme Pharma Inc | COM | 45790W108 | 12,927,000 | 2,709,987 | SH | SOLE | 2,709,987 | 0 | 0 | |||
| Instil Bio Inc | COM | 45783C101 | 27,709,000 | 5,997,657 | SH | SOLE | 5,997,657 | 0 | 0 | |||
| LianBio | SPONS ADR | 53000N108 | 11,617,000 | 5,378,341 | SH | SOLE | 5,378,341 | 0 | 0 | |||
| Lyra Therapeutics Inc | COM | 55234L105 | 5,222,000 | 924,170 | SH | SOLE | 924,170 | 0 | 0 | |||
| Marinus Pharmaceuticals Inc | COM | 56854Q200 | 15,279,000 | 3,156,803 | SH | SOLE | 3,156,803 | 0 | 0 | |||
| Provention Bio Inc | COM | 74374N102 | 4,475,000 | 1,118,653 | SH | SOLE | 1,118,653 | 0 | 0 | |||
| Rallybio Corp | COM | 75120L100 | 2,027,000 | 268,532 | SH | SOLE | 268,532 | 0 | 0 | |||
| Relmada Therapeutics Inc | COM | 75955J402 | 43,109,000 | 2,270,072 | SH | SOLE | 2,270,072 | 0 | 0 | |||
| Savara Inc | COM | 805111101 | 6,259,000 | 4,117,530 | SH | SOLE | 4,117,530 | 0 | 0 | |||
| Travere Therapeutics Inc | COM | 89422G107 | 41,460,000 | 1,711,102 | SH | SOLE | 1,711,102 | 0 | 0 | |||
| Trevi Therapeutics Inc | COM | 89532M101 | 8,571,000 | 3,050,022 | SH | SOLE | 3,050,022 | 0 | 0 | |||
| Tricida Inc | COM | 89610F101 | 69,039,000 | 7,132,079 | SH | SOLE | 7,132,079 | 0 | 0 | |||
| Viridian Therapeutics Inc | COM | 92790C104 | 21,438,000 | 1,852,919 | SH | SOLE | 1,852,919 | 0 | 0 | |||
| VistaGen Therapeutics Inc | COM | 92840H202 | 18,214,000 | 20,697,286 | SH | SOLE | 20,697,286 | 0 | 0 | |||
| Xenon Pharmaceuticals Inc | COM | 98420N105 | 913,000 | 30,000 | SH | SOLE | 30,000 | 0 | 0 | |||